Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Unfit/17p-Deleted CLL
NCT02015208Phase 2Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Apr 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic lymphocytic leukemia (CLL), sponsored by Sunnybrook Health Sciences Centre. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02015208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015208.